- Previous Close
0.5615 - Open
0.5641 - Bid 0.5123 x 400
- Ask 0.5676 x 400
- Day's Range
0.5365 - 0.5842 - 52 Week Range
0.5050 - 5.6200 - Volume
626,745 - Avg. Volume
576,522 - Market Cap (intraday)
21.998M - Beta (5Y Monthly) 0.28
- PE Ratio (TTM)
-- - EPS (TTM)
-3.4600 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.83
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
www.bioxceltherapeutics.comRecent News: BTAI
View MorePerformance Overview: BTAI
Trailing total returns as of 10/2/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BTAI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BTAI
View MoreValuation Measures
Market Cap
22.00M
Enterprise Value
68.99M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.29
Price/Book (mrq)
--
Enterprise Value/Revenue
28.71
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-63.62%
Return on Equity (ttm)
--
Revenue (ttm)
2.4M
Net Income Avi to Common (ttm)
-107.83M
Diluted EPS (ttm)
-3.4600
Balance Sheet and Cash Flow
Total Cash (mrq)
56.27M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-65.6M
Research Analysis: BTAI
View MoreCompany Insights: BTAI
BTAI does not have Company Insights